Hudson Bay Capital Management’s Standard BioTools LAB Stock Holding History

Hudson Bay Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.7K	Buy	+64,040	New	+$60.5K	﹤0.01%	1220

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Hudson Bay Capital Management's LAB Position: Q2 2026 in Review

Hudson Bay Capital Management opened a new position in Standard BioTools (LAB) in Q2 2026: 64,040 shares worth $52.7K. The stake represents ﹤0.01% of the portfolio and ranks #1220 among its holdings.

143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Hudson Bay Capital Management held 64,040 shares of Standard BioTools worth $52.7K as of Q2 2026.
Standard BioTools was a new Hudson Bay Capital Management position in Q2 2026.
Standard BioTools made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #1220 holding.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.